Cabot Wealth Management
AXSM icon

Cabot Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Cabot Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.03M Hold
5,560
– – 0.1% 100
2026
Q2 		$1.36M Hold
5,560
– – 0.14% 85
2026
Q1 		$940K Hold
5,560
– – 0.11% 94
2025
Q4 		$1.02M Hold
5,560
– – 0.11% 95
2025
Q3 		$675K Buy
+5,560
New +$626K 0.07% 102

Other funds holding AXSM

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Cabot Wealth Management's AXSM Position: Q3 2026 in Review

Cabot Wealth Management held its Axsome Therapeutics (AXSM) position steady in Q3 2026 at 5,560 shares worth $1.03M. The position accounts for 0.1% of the portfolio, ranked #100.

Cabot Wealth Management first reported a position in AXSM in Q3 2025 and has held it in 5 quarters since. The position peaked at $1.36M in Q2 2026. 183 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Cabot Wealth Management held 5,560 shares of Axsome Therapeutics worth $1.03M as of Q3 2026.
  • Cabot Wealth Management left its Axsome Therapeutics share count unchanged in Q3 2026.
  • Axsome Therapeutics made up 0.1% of Cabot Wealth Management's portfolio in Q3 2026, its #100 holding.
  • Cabot Wealth Management first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Cabot Wealth Management's Axsome Therapeutics position peaked at $1.36M in Q2 2026.
  • 183 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Cabot Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.